featured
Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer in Premenopausal Women
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Breast Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
Breast Cancer Res 2021 Aug 23;23(1)87, P Neven, HS Rugo, SM Tolaney, H Iwata, M Toi, MP Goetz, PA Kaufman, Y Lu, N Haddad, KC Hurt, GW SledgeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.